ABTI.US Alterola Biotech Inc
- Market cap
- USD 292K
- P/E
- -
- P/B
- 0.52x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2024.
Is ABTI.US undervalued?
Graham numberThe Graham number of Alterola Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alterola Biotech Inc fundamental analysis
No fundamental analysis for Alterola Biotech Inc yet.
Alterola Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alterola Biotech Inc
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech, Inc. is based in Birkenhead, t…
Full company profileAlterola Biotech Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alterola Biotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -20.4K | -14.7K | -49.1K | -14.7K | -258K | -123K | -330K | -6.47M | -1.90M | -2.11M | -2.32M |
| EBITDA | -19.9K | - | -46.5K | -11.6K | - | -258K | -251K | -6.47M | -1.70M | -2.11M | - |
| Net Income | -36.1K | -22.6K | -67.6K | -22.6K | -259K | -133K | -172K | -6.47M | -1.54M | -2.37M | -2.52M |
| EPS | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 8.31K | 2.58K | 0.00 | 2.58K | 14.7K | 50.7K | 15.3K | 12.1M | 12.4M | 3.66K | 1.36M |
| Total Liabilities | 250K | 267K | 295K | 267K | 217K | 106K | 338K | 1.20M | 2.28M | 1.33M | 3.62M |
| Shareholders' Equity | -241K | -264K | -295K | -264K | -203K | -55.6K | -323K | 10.9M | 10.1M | -1.33M | -2.05M |
| Cash & Short-term Investments | 2.63K | 0.00 | 0.00 | - | - | - | 63.8K | 63.8K | 8.89K | 2.65K | 82.7K |
| Total Debt | 150K | - | - | 175K | - | 20.0K | - | 164K | 1.41M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.4K | -27.6K | -20.0K | -27.6K | 0.00 | -20.0K | 44.3K | 44.3K | -1.04M | -1.45M | -2.14M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 140K | 140K | 0.00 | 0.00 |
| Free Cash Flow | -17.4K | - | 0.00 | -27.6K | 0.00 | -20.0K | 44.3K | 44.3K | -1.18M | -1.45M | -2.26M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | - | - | -59.2% | -15.3% | - | - |
| ROA | -434.5% | -874.1% | - | -874.1% | -1,754.9% | -262.2% | -1,123.0% | -53.4% | -12.5% | -64,820.6% | -184.4% |
| Debt to Equity | - | - | - | - | - | - | - | 0.02x | 0.14x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alterola Biotech Inc dividends
Alterola Biotech Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 10:1 on Aug 26, 2010.
Who owns Alterola Biotech Inc
- Insiders 90.41%
- Institutions 0.00%
- Public & others 9.59%
- Shares outstanding 1.46B
- Free float 377M
Alterola Biotech Inc company profile
- Company name
- Alterola Biotech Inc
- Ticker
- ABTI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- March
- Address
- 47 Hamilton Square, Birkenhead, United Kingdom, CH41 5AR
- Phone
- 44 1516 019 477
- Website
- alterola-abti.com
About Alterola Biotech Inc
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailability, solubility, and stability. Alterola Biotech, Inc. is based in Birkenhead, the United Kingdom.
Alterola Biotech Inc management
4- Mr. David John Hitchcock O.B.E.Chief Executive Officer · born 1963
- Mr. Nathan ThompsonCFO & Secretary · born 1975
- Mr. Colin G. Stott B.Sc.COO & Director · born 1966
- Mr. Dominic SchillerIP Counsel, Chief IP Officer & Director · born 1965